VXM10

VXM10 is an investigational oral T-cell immunotherapy developed by Vaximm AG, designed to target the tumor vasculature by inducing a specific immune response against Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). The drug utilizes a live-attenuated *Salmonella typhimurium* strain (Ty21a) as a bacterial vector to deliver a DNA plasmid encoding human VEGFR2. Upon oral administration, the bacteria are taken up by Peyer's patches in the gut, where the plasmid is expressed, leading to the activation of VEGFR2-specific cytotoxic T cells. These T cells then target and destroy VEGFR2-expressing endothelial cells within the tumor's neo-vasculature, thereby inhibiting angiogenesis and tumor growth. VXM10 has been evaluated in clinical trials for various solid tumors, including glioblastoma and colorectal cancer, often in combination with immune checkpoint inhibitors like avelumab.

Other names

Oral VEGFR2 vaccine